Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis

Journal of Clinical Oncology

Volumn 30, Issue 22, 2012, Pages 2788-2797

  Mauguen, Audrey ^a   Le Péchoux, Cécile ^a   Saunders, Michele I ^b   Schild, Steven E ^d   Turrisi, Andrew T ^e   Baumann, Michael ^f   Sause, William T ^g   Ball, David ^h   Belani, Chandra P ^j   Bonner, James A ^l   Zajusz, Aleksander ^m   Dahlberg, Suzanne E ⁿ   Nankivell, Matthew ^c   Mandrekar, Sumithra J ^o   Paulus, Rebecca ^k   Behrendt, Katarzyna ^m   Koch, Rainer ^f   Bishop, James F ⁱ   Dische, Stanley ^b   Arriagada, Rodrigo ^a,p   De Ruysscher, Dirk ^q   Pignon, Jean Pierre ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d MAYO CLINIC   (United States)

^e SINAI GRACE HOSPITAL   (United States)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g INTERMOUNTAIN MEDICAL CENTER   (United States)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ VICTORIAN COMPREHENSIVE CANCER CENTRE   (Australia)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k RADIATION THERAPY ONCOLOGY GROUP   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m INSTITUTE OF ONCOLOGY   (Poland)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o North Central Cancer Treatment Group Rochester   (United States)

^p KAROLINSKA INSTITUTE   (Sweden)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL;

ACCELERATED RADIOTHERAPY; ACUTE TOXICITY; BLOOD TOXICITY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; CONVENTIONAL RADIOTHERAPY; DISTANT FAILURE FREE SURVIVAL; ESOPHAGUS DISEASE; HUMAN; HYPERFRACTIONATED RADIOTHERAPY; INDUCTION CHEMOTHERAPY; INTERMETHOD COMPARISON; LOCAL RECURRENCE FREE SURVIVAL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ESOPHAGUS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 84864564911     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.6677     Document Type: Review

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005 (Pubitemid 40372904)
2. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784- 796, 2007
3. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24:4539-4544, 2006 (Pubitemid 46630948)
4. Stuschke M, Pöttgen C: Localized small-cell lung cancer: Which type of thoracic radiotherapy and which time schedule. Lung Cancer 45:S133-S137, 2004 (suppl 2)
5. Arriagada R, Komaki R, Cox JD: Radiation dose escalation in non-small cell carcinoma of the lung. Semin Radiat Oncol 14:287-291, 2004 (Pubitemid 39536023)
6. Peters L, Ang K: The role of altered fractionation in head and neck cancer. Semin Radiat Oncol 2:180-194, 1992
7. Horiot JC, Bontemps P, van den Bogaert W, et al: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves locoregional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 44:111-121, 1997 (Pubitemid 27345198)
8. Bourhis J, Overgaard J, Audry H, et al: Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368:843-854, 2006 (Pubitemid 44292807)
9. Early Breast Cancer Trialists Collaborative Group: Effect of systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
10. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992
11. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patient from 52 randomized clinical trials-Non-Small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
12. Aupérin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484, 1999 (Pubitemid 29372887)
13. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008
14. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
15. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of randomised clinical trials. Prog Cardiovasc Dis 27:335-371, 1985 (Pubitemid 15107153)
16. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002 (Pubitemid 34746062)
17. Stewart LA, Parmar MK: Meta-analysis of the literature or meta-analysis of individual patient data: Is there a difference? Lancet 341:418-422, 1993 (Pubitemid 23048157)
18. Fisher DJ, Copas AJ, Tierney JF, et al: A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol 64:949-967, 2011
19. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679-694, 1989
20. Schild SE, Bonner JA, Hillman S, et al: Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol 25:3124-3129, 2007 (Pubitemid 47218061)
21. Bentzen SM, Saunders MI, Dische S: From CHART to CHARTWEL in non-small cell lung cancer: Clinical radiobiological modelling of the expected change in outcome. Clin Oncol (R Coll Radiol) 14:372-381, 2002
22. Fu S, Jiang GL, Wang LJ: Hyperfractionated irradiation for non-small cell lung cancer (NSCLC): A phase III clinical trial [in Chinese]. Zhonghua Zhong Liu Za Zhi 16:306-309, 1994 (Pubitemid 24353439)
23. Sun LM, Leung SW, Wang CJ, et al: Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: Preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 47:413-418, 2000 (Pubitemid 30236383)
24. Turrisi AT 3rd, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999 (Pubitemid 29063268)
25. Schild SE, Bonner JA, Shanahan TG, et al: Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:943-951, 2004 (Pubitemid 38834286)
26. Sause WT, Kolesar P, Taylor S 4th, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000 (Pubitemid 30111583)
27. Ball D, Bishop J, Smith J, et al: A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial. Radiother Oncol 52:129-136, 1999 (Pubitemid 29461080)
28. Saunders M, Dische S, Barrett A, et al: Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in nonsmall cell lung cancer: Mature data from the randomised multicentre trial-CHART Steering committee. Radiother Oncol 52:137-148, 1999 (Pubitemid 29461081)
29. Bonner JA, McGinnis WL, Stella PJ, et al: The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced non-small cell lung cancer: Results of a North Central Cancer Treatment Group phase III study. Cancer 82:1037-1048, 1998 (Pubitemid 28136515)
30. Schild SE, Stella PJ, Geyer SM, et al: Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:370-378, 2002 (Pubitemid 35286800)
31. Baumann M, Herrmann T, Koch R, et al: On behalf of the CHARTWEL-bronchus group: Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionatedaccelerated vs conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 100:76-85, 2011
32. Belani CP, Wang W, Johnson DH, et al: Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23:3760-3767, 2005
33. Zajusz A, Behrendt K, Nowicka E, et al: Early results of continuous accelerated radiotherapy (CAIR) for LA-NSCLC patients. Radiother Oncol 81:S386, 2006 (suppl 1)
34. Aupérin A, Le Péchoux C, Rolland E, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181-2190, 2010
35. Werner-Wasik M: Treatment-related esophagitis. Semin Oncol 32:S60-S66, 2005 (suppl 3)
36. Kerr KM, Lamb D: Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 50:343-349, 1984 (Pubitemid 14063885)
37. Trott KR: Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys 19:1071-1075, 1990
38. Mehta M, Scrimger R, Mackie R: A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 49:23-33, 2001 (Pubitemid 32041273)
39. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limiteddisease small-cell lung cancer. J Clin Oncol 24:1057-1063, 2006 (Pubitemid 46638802)
40. De Ruysscher D, Faivre-Finn C, Nestle U, et al: European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 28:5301-5310, 2010